fda warning about semaglutide approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease Ozempic started the weight-loss drug

Common side effects of Semaglutide and Tirzepatide are usually mild and temporary, and may include: Nausea Vomiting Diarrhea Constipation Abdominal pain Decreased appetite Indigestion Most side effects improve as your body adjusts to treatment

A computer task measured attraction to high-fat savory foods and showed no group difference at any point

Despite their therapeutic promise, the impact of semaglutide on key endocrine and metabolic developmental processes during this period is not yet fully understood

Titration Minimizes Side Effects The stepwise dose increases allow the body to adjust progressively, reducing gastrointestinal side effect intensity